ViralClear adds St. David’s HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19

Ads

You May Also Like

VELTASSA® APPROVED FOR MARKETING IN SWITZERLAND FOR THE TREATMENT OF HYPERKALAEMIA

Klicken Sie hier für Deutsch Veuillez cliquer ici pour français SWISSMEDIC HAS APPROVED PATIROMER ...

DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients

Press ReleaseMontrouge, France, February 26, 2018                                                                                                                                                                           DBV Technologies Announces Results from Phase ...